胰腺癌的个体化RNA药物研究报告
2021-3-16 来源：本站原创 浏览次数：次ClinCancerRes.Apr1;24(7):-
EnglishversionPurpose:Sincedrugresponsesvarybetweenpatients,itiscrucialtodeveloppre-clinicalorco-clinicalstrategiesthatforecastpatientresponse.Inthisstudy,wetestedwhetherRNA-basedtherapeuticsweresuitableforpersonalizedmedicinebyusingpatient-derived-organoid(PDO)andpatient-derived-xenograft(PDX)models.
ExperimentalDesign:WeperformedmicroRNA(miRNA)profilingofPDXsamplestodeterminethestatusofmiRNAderegulationinindividualpancreaticductaladenocarcinoma(PDAC)patients.TodeliverpersonalizedRNA-based-therapytargetingoncogenicmiRNAsthatformpartofthis
健康热线：